These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 26162437)
21. Emerging role of epigenetics in systemic sclerosis pathogenesis. Ciechomska M; van Laar JM; O'Reilly S Genes Immun; 2014 Oct; 15(7):433-9. PubMed ID: 25030429 [TBL] [Abstract][Full Text] [Related]
22. Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential. Tsou PS; Varga J; O'Reilly S Nat Rev Rheumatol; 2021 Oct; 17(10):596-607. PubMed ID: 34480165 [TBL] [Abstract][Full Text] [Related]
23. Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis. Asano Y Int J Biochem Cell Biol; 2015 Oct; 67():86-91. PubMed ID: 26055516 [TBL] [Abstract][Full Text] [Related]
24. [A Uuifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 - the development of a new animal model of systemic sclerosis -]. Asano Y Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):475-87. PubMed ID: 25748132 [TBL] [Abstract][Full Text] [Related]
25. Genetic factors and systemic sclerosis. Murdaca G; Contatore M; Gulli R; Mandich P; Puppo F Autoimmun Rev; 2016 May; 15(5):427-32. PubMed ID: 26826434 [TBL] [Abstract][Full Text] [Related]
26. [Research progress in epigenetic studies on systemic sclerosis]. Long Y; Chen W; Du Q; Zuo X; Zhu H Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 43(12):1369-1375. PubMed ID: 30643055 [TBL] [Abstract][Full Text] [Related]
27. Global hypomethylation pattern in systemic sclerosis: An application for absolute quantification of epigenetic DNA modification products by 2D-UPLC-MS/MS. Dal-Bekar NE; Siomek-Gorecka A; Gackowski D; Köken-Avşar A; Yarkan-Tuğsal H; Birlik M; İşlekel H Clin Immunol; 2022 Jun; 239():108997. PubMed ID: 35398518 [TBL] [Abstract][Full Text] [Related]
28. Epigenetic Control of Scleroderma: Current Knowledge and Future Perspectives. Tsou PS Curr Rheumatol Rep; 2019 Dec; 21(12):69. PubMed ID: 31813068 [TBL] [Abstract][Full Text] [Related]
29. The Role of Epigenetic Modifications in Systemic Sclerosis: A Druggable Target. Henderson J; Distler J; O'Reilly S Trends Mol Med; 2019 May; 25(5):395-411. PubMed ID: 30858032 [TBL] [Abstract][Full Text] [Related]
35. Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis. Tsai CY; Hsieh SC; Wu TH; Li KJ; Shen CY; Liao HT; Wu CH; Kuo YM; Lu CS; Yu CL Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349208 [TBL] [Abstract][Full Text] [Related]
36. Broadening our understanding of genetic risk for scleroderma/systemic sclerosis by querying the chromatin architecture surrounding the risk haplotypes. Poppenberg KE; Tutino VM; Tarbell E; Jarvis JN BMC Med Genomics; 2021 Apr; 14(1):114. PubMed ID: 33894768 [TBL] [Abstract][Full Text] [Related]
37. Epigenetic Modifications and Therapy in Multiple Sclerosis. Aslani S; Jafari N; Javan MR; Karami J; Ahmadi M; Jafarnejad M Neuromolecular Med; 2017 Mar; 19(1):11-23. PubMed ID: 27382982 [TBL] [Abstract][Full Text] [Related]
38. Epigenetic dysregulation in systemic lupus erythematosus. Liu A; La Cava A Autoimmunity; 2014 Jun; 47(4):215-9. PubMed ID: 24128164 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of X Chromosome Inactivation with Respect to HLA Genetic Susceptibility in Rheumatoid Arthritis and Systemic Sclerosis. Kanaan SB; Onat OE; Balandraud N; Martin GV; Nelson JL; Azzouz DF; Auger I; Arnoux F; Martin M; Roudier J; Ozcelik T; Lambert NC PLoS One; 2016; 11(6):e0158550. PubMed ID: 27355582 [TBL] [Abstract][Full Text] [Related]